Autolus holder reports 11.3% passive stake
Autolus Therapeutics plc received an updated ownership report from MAK Capital and related entities.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Autolus Therapeutics plc received an updated ownership report from MAK Capital and related entities. The group reports beneficial ownership of 30,005,343 American Depositary Shares, representing 11.3% of Autolus’s ordinary shares, based on 266,143,286 ordinary shares outstanding as of November 11, 2025.
The shares are held with shared voting and dispositive power and no sole authority. The reporting parties certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Autolus, indicating a passive investment intent.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in Autolus Therapeutics plc (AUTL) does MAK Capital report?
Is MAK Capital’s stake in Autolus (AUTL) reported as passive or activist?
Who are the reporting persons in the Autolus (AUTL) Schedule 13G/A?
What class of Autolus (AUTL) securities is covered by this Schedule 13G/A?
AI-generated analysis. How Rhea-AI works. Not financial advice.